Thalidomide: Current status

Indian Journal of Dermatology, Venereology and Leprology

Volumn 72, Issue 1, 2006, Pages 75-80

  Shanbhag, Prashasti S ^a   Viswanath, Vishalakshi ^a   Torsekar, R G ^a  

^a Department of Dermatology   (India)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ACETYLCHOLINE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CELL ADHESION MOLECULE; CHLORPROMAZINE; CLOFAZIMINE; GRISEOFULVIN; HISTAMINE; LENALIDOMIDE; PROSTAGLANDIN E2; PROSTAGLANDIN F2; PROTEINASE INHIBITOR; RESERPINE; RIFAMPICIN; SEDATIVE AGENT; SEROTONIN; STEROID; THALIDOMIDE;

ALLERGIC VASCULITIS; ANOPHTHALMIA; ANTIINFLAMMATORY ACTIVITY; APHTHOUS ULCER; APLASIA; AUDITORY CANAL; BEHCET DISEASE; BRADYCARDIA; BREAST CANCER; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONSTIPATION; CONVULSION; CROHN DISEASE; DEEP VEIN THROMBOSIS; DIZZINESS; DOSE RESPONSE; DOWN REGULATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRY SKIN; ERYTHEMA NODOSUM LEPROSUM; EXFOLIATIVE DERMATITIS; FACIAL NERVE PARALYSIS; FOOT EDEMA; GASTROINTESTINAL MALFORMATION; GENITAL MALFORMATION; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; HYPERTENSION; HYPOPLASIA; HYPOTENSION; HYPOTHYROIDISM; IMMUNOMODULATION; INCREASED APPETITE; LEUKEMIA; LUNG EMBOLISM; MEASLES LIKE RASH; MENSTRUATION DISORDER; MICROPHTHALMIA; MOOD DISORDER; MULTIPLE MYELOMA; NAIL DISEASE; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOCOMELIA; PROSTATE CANCER; PRURIGO; PRURITUS; PYODERMA GANGRENOSUM; REVIEW; SEDATION; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; SKIN TOXICITY; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; TERATOGENICITY; THROMBOCYTOPENIC PURPURA; THROMBOEMBOLISM; TREATMENT OUTCOME; URINARY TRACT MALFORMATION; URTICARIA; WEIGHT GAIN; XEROSTOMIA;

EID: 32044466681     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.19732     Document Type: Review

References (27)

1. Radomsky CL, Levine N. Thalidomide. Dermatol Clin 2001;19:87-103.
2. Tseng S, Pak G, Washenik K, Pomeranz MK, and Shupack JL. Rediscovering thalidomide: a review of it's mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35:969-79.
3. Perri AJ III, Hsu S. A review of thalidomide's history and current dermatological applications. Dermatology Online Journal; 9(3):5. Available at http://dermatology.cdlib.org/93/reviews/thalidomide/hsu.html
4. Wu, JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: dermatological indications, mechanism of action and side effects. Br J Dermatol 2005;153:254-73.
5. Moncada B, Baranda ML, Gonzalez-Amaro R, Urbina R, Loredo CE. Thalidomide - effect on T-cell subsets a possible mechanism of action. Int J Lep 1985;53:201-5.
6. Knable AL Jr. Miscellaneous systemic drugs. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy, 1st ed. Philadelphia: WB Saunders; 2001. p. 445-54.
7. Waters MF. An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum. Lepr Rev 1971;42:26-42.
8. Sheskin J, Convit J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr 1969;37:135-46.
9. Convit J, Soto JM, Sheskin J. Thalidomide therapy in the lepra reaction. Int J Lepr 1967;35:446-51.
10. Moreira AL, Gilla K. Comparison of pentoxyphylline, thalidomide and prednisone in the treatment of ENL. Int J Lep 1998;66:61-5.
11. Parikh DA, Maniar JK, Ganapathi R. Thalidomide in leprosy and some dermatological conditions-a review. Indian J Lep 1985;57:862-7.
12. Parikh DA, Ganapathi R, Revankar CR. Thalidomide in leprosy-study of 94 cases. Indian J Lep 1986;58:560-6.
13. Pearson JM, Vedagiri M. Treatment of moderately severe erythema nodosum leprosum with thalidomide- a double blind controlled trial. Lep Rev 1969;40:111-6.
14. Sheskin J, Magora A, Sagher F. Motor conduction velocity studies in patients with leprosy reaction treated with thalidomide and other drugs. Int J Lep 1969;37:359-63.
15. van den Broek H. Treatment of prurigo nodularis with thalidomide. Arch Dermatol 1980;116:571-2.
16. Bulic OS, Fassihs H, Mellerio JE, McGrath JA, Atherton DJ. Thalidomide in the management of epidermolysis bullosa pruriginosa. Br J Dermatol 2005;152:1332-4.
17. Letsinger JA, McCarty MA, Jorizzo JL. Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. J Am Acad Dermatol 2005;52:500-8.
18. Ghigliotti G, Repetto T, Farris A, Roy MT, De Marchi R. Thalidomide: treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus. J Am Acad Dermatol 1993;28:271-3.
19. Radeff B, Kuffer R, Samson J. Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: successful treatment with thalidomide. J Am Acad Dermatol 1990;23:523-5.
20. Youle M, Clarbour J, Farthing C, Connolly M, Hawkins D, Staughton R, et al. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Br Med J 1989;298:432.
21. Caradona S, Jacob H. Thalidomide as a potential treatment for scleromyxoedema. Arch Dermatol 2004;140:277-80.
22. Sansbury JC, Cocuroccia B, Jorizzo J, Gubinelli E, Gisondi P, Girolomoni G. Treatment of recalcitrant scleromyxoedema with thalidomide in 3 patients. J Am Acad Dermatol 2004;51:126-31.
23. Jouanique C, Reygagne P, Bachelez H, Dubertret L. Thalidomide is ineffective in the treatment of lichen planopilaris. J Am Acad Dermatol 2004;51:480-1.
24. Brightman L, Demiere MF. Thalidomide in mycosis fungoides. J Am Acad Dermatol 2005;52:1100-1.
25. Powell RJ, Gardner-Medwin JM. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 1994;70:901-4.
26. Quilitz R, Pharm D. Thalidomide in oncology: the peril and the promise. J Moffit Cancer Centre 1999;6(5). Available at http://www.moffit.usf.edu/pubs/ ccj/index.html
27. Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 2005;7:E14-E19. Available at http://www.aapsj.org